RecallRadar

FDA Drug recall D-1545-2022

Budesonide Inhalation Suspension 0.25mg/2mL, For Inhalation Only, Rx Only, 1 envelope x five 2 mL Single Dose Ampules per pouch, Sterile Su…

On 2022-10-05 the FDA classified a Class II recall of Budesonide Inhalation Suspension 0.25mg/2mL, For Inhalation Only, Rx Only, 1 envelope x five 2 mL Single Dose Ampules per pouch, Sterile Su… by Cipla, citing lack of Assurance of Sterility.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-1545-2022
ClassificationClass II
Statusterminated
Initiated2022-09-15
Published2022-10-05
Last updated2026-09-13 11:52 UTC
CompanyCipla
DistributionUS

Product

Budesonide Inhalation Suspension 0.25mg/2mL, For Inhalation Only, Rx Only, 1 envelope x five 2 mL Single Dose Ampules per pouch, Sterile Suspension, Manufactured by: Cipla Ltd., India, Manufactured for Cipla USA Inc., Warren NJ, NDC# 69097-318-86.

Reason

Lack of Assurance of Sterility

Identifiers

ndc69097-318-86
ndc69097-318-87
ndc69097-318-32
ndc69097-318-53
ndc69097-319-86
ndc69097-319-87
ndc69097-319-32
ndc69097-319-53
ndc69097-321-86
ndc69097-321-87
ndc69097-321-32
ndc69097-321-53
code_infoLot #s: GA20080, GA20081, GA20094, Exp. 01/2024

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1545-2022%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.